Stat5 is critical for the development and maintenance of myeloproliferative neoplasm initiated by Nf1 deficiency

Zohar Sachs, Raha A. Been, Krista J. Decoursin, Hanh T. Nguyen, Nurul A. Mohd Hassan, Klara E. Noble-Orcutt, Craig E. Eckfeldt, Emily J. Pomeroy, Ernesto Diaz-Flores, Jennifer L. Geurts, Miechaleen D. Diers, Diane E. Hasz, Kelly J. Morgan, Margaret L. Macmillan, Kevin M. Shannon, David A. Largaespada, Stephen M. Wiesner

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

Juvenile myelomonocytic leukemia is a rare myeloproliferative neoplasm characterized by hyperactive RAS signaling. Neurofibromin1 (encoded by the NF1 gene) is a negative regulator of RAS activation. Patients with neurofibromatosis type 1 harbor loss-of-function mutations in NF1 and have a 200- to 500-fold increased risk of juvenile myelomonocytic leukemia. Leukemia cells from patients with juvenile myelomonocytic leukemia display hypersensitivity to certain cytokines, such as granulocyte-macrophage colony-stimulating factor. The granulocyte-macrophage colony-stimulating factor receptor utilizes pre-associated JAK2 to initiate signals after ligand binding. JAK2 subsequently activates STAT5, among other downstream effectors. Although STAT5 is gaining recognition as an important mediator of growth factor signaling in myeloid leukemias, the contribution of STAT5 to the development of hyperactive RAS-initiated myeloproliferative disease has not been well described. In this study, we investigated the consequence of STAT5 attenuation via genetic and pharmacological approaches in Nf1-deficient murine models of juvenile myelomonocytic leukemia. We found that homozygous Stat5 deficiency extended the lifespan of Nf1-deficient mice and eliminated the development of myeloproliferative neoplasm associated with Nf1 gene loss. Likewise, we found that JAK inhibition with ruxolitinib attenuated myeloproliferative neoplasm in Nf1-deficient mice. Finally, we found that primary cells from a patient with KRAS-mutant juvenile myelomonocytic leukemia displayed reduced colony formation in response to JAK2 inhibition. Our findings establish a central role for STAT5 activation in the pathogenesis of juvenile myelomonocytic leukemia and suggest that targeting this pathway may be of clinical utility in these patients.

Original languageEnglish (US)
Pages (from-to)1190-1199
Number of pages10
JournalHaematologica
Volume101
Issue number10
DOIs
StatePublished - Sep 30 2016

Fingerprint

Juvenile Myelomonocytic Leukemia
Maintenance
Neoplasms
Neurofibromatosis 1 Genes
Granulocyte-Macrophage Colony-Stimulating Factor Receptors
Neurofibromatosis 1
Myeloid Leukemia
Granulocyte-Macrophage Colony-Stimulating Factor
Intercellular Signaling Peptides and Proteins
Hypersensitivity
Leukemia
Pharmacology
Cytokines
Ligands
Mutation

Cite this

Stat5 is critical for the development and maintenance of myeloproliferative neoplasm initiated by Nf1 deficiency. / Sachs, Zohar; Been, Raha A.; Decoursin, Krista J.; Nguyen, Hanh T.; Mohd Hassan, Nurul A.; Noble-Orcutt, Klara E.; Eckfeldt, Craig E.; Pomeroy, Emily J.; Diaz-Flores, Ernesto; Geurts, Jennifer L.; Diers, Miechaleen D.; Hasz, Diane E.; Morgan, Kelly J.; Macmillan, Margaret L.; Shannon, Kevin M.; Largaespada, David A.; Wiesner, Stephen M.

In: Haematologica, Vol. 101, No. 10, 30.09.2016, p. 1190-1199.

Research output: Contribution to journalArticle

Sachs, Z, Been, RA, Decoursin, KJ, Nguyen, HT, Mohd Hassan, NA, Noble-Orcutt, KE, Eckfeldt, CE, Pomeroy, EJ, Diaz-Flores, E, Geurts, JL, Diers, MD, Hasz, DE, Morgan, KJ, Macmillan, ML, Shannon, KM, Largaespada, DA & Wiesner, SM 2016, 'Stat5 is critical for the development and maintenance of myeloproliferative neoplasm initiated by Nf1 deficiency', Haematologica, vol. 101, no. 10, pp. 1190-1199. https://doi.org/10.3324/haematol.2015.136002
Sachs, Zohar ; Been, Raha A. ; Decoursin, Krista J. ; Nguyen, Hanh T. ; Mohd Hassan, Nurul A. ; Noble-Orcutt, Klara E. ; Eckfeldt, Craig E. ; Pomeroy, Emily J. ; Diaz-Flores, Ernesto ; Geurts, Jennifer L. ; Diers, Miechaleen D. ; Hasz, Diane E. ; Morgan, Kelly J. ; Macmillan, Margaret L. ; Shannon, Kevin M. ; Largaespada, David A. ; Wiesner, Stephen M. / Stat5 is critical for the development and maintenance of myeloproliferative neoplasm initiated by Nf1 deficiency. In: Haematologica. 2016 ; Vol. 101, No. 10. pp. 1190-1199.
@article{15ba3061570244e0a87d9ab013c2bd5e,
title = "Stat5 is critical for the development and maintenance of myeloproliferative neoplasm initiated by Nf1 deficiency",
abstract = "Juvenile myelomonocytic leukemia is a rare myeloproliferative neoplasm characterized by hyperactive RAS signaling. Neurofibromin1 (encoded by the NF1 gene) is a negative regulator of RAS activation. Patients with neurofibromatosis type 1 harbor loss-of-function mutations in NF1 and have a 200- to 500-fold increased risk of juvenile myelomonocytic leukemia. Leukemia cells from patients with juvenile myelomonocytic leukemia display hypersensitivity to certain cytokines, such as granulocyte-macrophage colony-stimulating factor. The granulocyte-macrophage colony-stimulating factor receptor utilizes pre-associated JAK2 to initiate signals after ligand binding. JAK2 subsequently activates STAT5, among other downstream effectors. Although STAT5 is gaining recognition as an important mediator of growth factor signaling in myeloid leukemias, the contribution of STAT5 to the development of hyperactive RAS-initiated myeloproliferative disease has not been well described. In this study, we investigated the consequence of STAT5 attenuation via genetic and pharmacological approaches in Nf1-deficient murine models of juvenile myelomonocytic leukemia. We found that homozygous Stat5 deficiency extended the lifespan of Nf1-deficient mice and eliminated the development of myeloproliferative neoplasm associated with Nf1 gene loss. Likewise, we found that JAK inhibition with ruxolitinib attenuated myeloproliferative neoplasm in Nf1-deficient mice. Finally, we found that primary cells from a patient with KRAS-mutant juvenile myelomonocytic leukemia displayed reduced colony formation in response to JAK2 inhibition. Our findings establish a central role for STAT5 activation in the pathogenesis of juvenile myelomonocytic leukemia and suggest that targeting this pathway may be of clinical utility in these patients.",
author = "Zohar Sachs and Been, {Raha A.} and Decoursin, {Krista J.} and Nguyen, {Hanh T.} and {Mohd Hassan}, {Nurul A.} and Noble-Orcutt, {Klara E.} and Eckfeldt, {Craig E.} and Pomeroy, {Emily J.} and Ernesto Diaz-Flores and Geurts, {Jennifer L.} and Diers, {Miechaleen D.} and Hasz, {Diane E.} and Morgan, {Kelly J.} and Macmillan, {Margaret L.} and Shannon, {Kevin M.} and Largaespada, {David A.} and Wiesner, {Stephen M.}",
year = "2016",
month = "9",
day = "30",
doi = "10.3324/haematol.2015.136002",
language = "English (US)",
volume = "101",
pages = "1190--1199",
journal = "Haematologica",
issn = "0390-6078",
publisher = "Ferrata Storti Foundation",
number = "10",

}

TY - JOUR

T1 - Stat5 is critical for the development and maintenance of myeloproliferative neoplasm initiated by Nf1 deficiency

AU - Sachs, Zohar

AU - Been, Raha A.

AU - Decoursin, Krista J.

AU - Nguyen, Hanh T.

AU - Mohd Hassan, Nurul A.

AU - Noble-Orcutt, Klara E.

AU - Eckfeldt, Craig E.

AU - Pomeroy, Emily J.

AU - Diaz-Flores, Ernesto

AU - Geurts, Jennifer L.

AU - Diers, Miechaleen D.

AU - Hasz, Diane E.

AU - Morgan, Kelly J.

AU - Macmillan, Margaret L.

AU - Shannon, Kevin M.

AU - Largaespada, David A.

AU - Wiesner, Stephen M.

PY - 2016/9/30

Y1 - 2016/9/30

N2 - Juvenile myelomonocytic leukemia is a rare myeloproliferative neoplasm characterized by hyperactive RAS signaling. Neurofibromin1 (encoded by the NF1 gene) is a negative regulator of RAS activation. Patients with neurofibromatosis type 1 harbor loss-of-function mutations in NF1 and have a 200- to 500-fold increased risk of juvenile myelomonocytic leukemia. Leukemia cells from patients with juvenile myelomonocytic leukemia display hypersensitivity to certain cytokines, such as granulocyte-macrophage colony-stimulating factor. The granulocyte-macrophage colony-stimulating factor receptor utilizes pre-associated JAK2 to initiate signals after ligand binding. JAK2 subsequently activates STAT5, among other downstream effectors. Although STAT5 is gaining recognition as an important mediator of growth factor signaling in myeloid leukemias, the contribution of STAT5 to the development of hyperactive RAS-initiated myeloproliferative disease has not been well described. In this study, we investigated the consequence of STAT5 attenuation via genetic and pharmacological approaches in Nf1-deficient murine models of juvenile myelomonocytic leukemia. We found that homozygous Stat5 deficiency extended the lifespan of Nf1-deficient mice and eliminated the development of myeloproliferative neoplasm associated with Nf1 gene loss. Likewise, we found that JAK inhibition with ruxolitinib attenuated myeloproliferative neoplasm in Nf1-deficient mice. Finally, we found that primary cells from a patient with KRAS-mutant juvenile myelomonocytic leukemia displayed reduced colony formation in response to JAK2 inhibition. Our findings establish a central role for STAT5 activation in the pathogenesis of juvenile myelomonocytic leukemia and suggest that targeting this pathway may be of clinical utility in these patients.

AB - Juvenile myelomonocytic leukemia is a rare myeloproliferative neoplasm characterized by hyperactive RAS signaling. Neurofibromin1 (encoded by the NF1 gene) is a negative regulator of RAS activation. Patients with neurofibromatosis type 1 harbor loss-of-function mutations in NF1 and have a 200- to 500-fold increased risk of juvenile myelomonocytic leukemia. Leukemia cells from patients with juvenile myelomonocytic leukemia display hypersensitivity to certain cytokines, such as granulocyte-macrophage colony-stimulating factor. The granulocyte-macrophage colony-stimulating factor receptor utilizes pre-associated JAK2 to initiate signals after ligand binding. JAK2 subsequently activates STAT5, among other downstream effectors. Although STAT5 is gaining recognition as an important mediator of growth factor signaling in myeloid leukemias, the contribution of STAT5 to the development of hyperactive RAS-initiated myeloproliferative disease has not been well described. In this study, we investigated the consequence of STAT5 attenuation via genetic and pharmacological approaches in Nf1-deficient murine models of juvenile myelomonocytic leukemia. We found that homozygous Stat5 deficiency extended the lifespan of Nf1-deficient mice and eliminated the development of myeloproliferative neoplasm associated with Nf1 gene loss. Likewise, we found that JAK inhibition with ruxolitinib attenuated myeloproliferative neoplasm in Nf1-deficient mice. Finally, we found that primary cells from a patient with KRAS-mutant juvenile myelomonocytic leukemia displayed reduced colony formation in response to JAK2 inhibition. Our findings establish a central role for STAT5 activation in the pathogenesis of juvenile myelomonocytic leukemia and suggest that targeting this pathway may be of clinical utility in these patients.

UR - http://www.scopus.com/inward/record.url?scp=84989333097&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84989333097&partnerID=8YFLogxK

U2 - 10.3324/haematol.2015.136002

DO - 10.3324/haematol.2015.136002

M3 - Article

C2 - 27418650

AN - SCOPUS:84989333097

VL - 101

SP - 1190

EP - 1199

JO - Haematologica

JF - Haematologica

SN - 0390-6078

IS - 10

ER -